Valeant Pharmaceuticals Intl Inc (TSE:VRX)‘s stock had its “sector perform” rating reaffirmed by investment analysts at Royal Bank Of Canada in a note issued to investors on Tuesday. They presently have a C$35.00 price target on the specialty pharmaceutical company’s stock, down from their previous price target of C$36.00. Royal Bank Of Canada’s target price indicates a potential upside of 20.15% from the stock’s current price.

Several other equities analysts have also commented on the company. TD Securities reaffirmed a “buy” rating and issued a C$38.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, August 10th. Scotiabank decreased their target price on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a “sector perform” rating on the stock in a research note on Monday, July 25th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of C$39.17.

Analyst Recommendations for Valeant Pharmaceuticals Intl (TSE:VRX)

Shares of Valeant Pharmaceuticals Intl (TSE:VRX) traded down 3.09% during trading on Tuesday, hitting $29.13. The stock had a trading volume of 783,057 shares. Valeant Pharmaceuticals Intl has a 12 month low of $24.32 and a 12 month high of $232.98. The company’s 50 day moving average price is $35.34 and its 200 day moving average price is $34.99. The stock’s market cap is $10.12 billion.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Receive News & Stock Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related stocks with our FREE daily email newsletter.